Failure of Hypomethylating Agent-Based Therapy in Myelodysplastic SyndromesKADIA, Tapan M; JABBOUR, Elias; KANTARJIAN, Hagop et al.Seminars in oncology. 2011, Vol 38, Num 5, pp 682-692, issn 0093-7754, 11 p.Article

Recent Developments in Drug Therapy for Aplastic AnemiaWILLIS, Lauren; REXWINKLE, Amber; BRYAN, Jeffrey et al.The Annals of pharmacotherapy. 2014, Vol 48, Num 11, pp 1469-1478, issn 1060-0280, 10 p.Article

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experienceKANTARJIAN, Hagop; O'BRIEN, Susan; BORTHAKUR, Gautam et al.Blood. 2012, Vol 119, Num 9, pp 1981-1987, issn 0006-4971, 7 p.Article

Prognostic Significance of Alterations in IDH Enzyme Isoforms in Patients With AML Treated With High-Dose Cytarabine and IdarubicinRAVANDI, Farhad; PATEL, Keyur; XUEMEI WANG et al.Cancer. 2012, Vol 118, Num 10, pp 2665-2673, issn 0008-543X, 9 p.Article

A Phase 1 Dose-Escalation Study of ARRY-520, a Kinesin Spindle Protein Inhibitor, in Patients With Advanced Myeloid LeukemiasJEAN KHOURY, Hanna; GARCIA-MANERO, Guillermo; KARAN, Sharon et al.Cancer. 2012, Vol 118, Num 14, pp 3556-3564, issn 0008-543X, 9 p.Article

The Combination of a Histone Deacetylase Inhibitor with the Bcl-2 Homology Domain-3 Mimetic GX15-070 Has Synergistic Antileukemia Activity by Activating Both Apoptosis and AutophagyYUE WEI; KADIA, Tapan; GARCIA-MANERO, Guillermo et al.Clinical cancer research (Print). 2010, Vol 16, Num 15, pp 3923-3932, issn 1078-0432, 10 p.Article

Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemiaNAZHA, Aziz; CORTES, Jorge; FADERL, Stefan et al.Haematologica (Roma). 2012, Vol 97, Num 8, pp 1242-1245, issn 0390-6078, 4 p.Article

Clofarabine Plus Low-Dose Cytarabine Followed by Clofarabine Plus Low-Dose Cytarabine Alternating With Decitabine in Acute Myeloid Leukemia Frontline Therapy for Older PatientsFADERL, Stefan; RAVANDI, Farhad; BURGER, Jan et al.Cancer. 2012, Vol 118, Num 18, pp 4471-4477, issn 0008-543X, 7 p.Article

Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controlsVERSTOVSEK, Srdan; KANTARJIAN, Hagop M; PUNGOLINO, Ester et al.Blood. 2012, Vol 120, Num 6, pp 1202-1209, issn 0006-4971, 8 p.Article

Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic PhaseCORTES, Jorge E; JONES, Dan; KANTARJIAN, Hagop et al.Journal of clinical oncology. 2010, Vol 28, Num 3, pp 392-397, issn 0732-183X, 6 p.Article

Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemiaHUI YANG; KADIA, Tapan; KANTARJIAN, Hagop M et al.Blood. 2009, Vol 113, Num 9, pp 1892-1898, issn 0006-4971, 7 p.Article

Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patientsAL-KALI, Aref; KONOPLEV, Sergej; BORTHAKUR, Gautam et al.Haematologica (Roma). 2012, Vol 97, Num 2, pp 235-240, issn 0390-6078, 6 p.Article

Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndromeDIMICOLI, Sophie; JABBOUR, Elias; BORTHAKUR, Gautam et al.American journal of hematology. 2012, Vol 87, Num 1, pp 127-129, issn 0361-8609, 3 p.Article

Persistence of Cytogenetic Abnormalities at Complete Remission After Induction in Patients With Acute Myeloid Leukemia: Prognostic Significance and the Potential Role of Allogeneic Stem-Cell TransplantationYIMING CHEN; CORTES, Jorge; KADIA, Tapan et al.Journal of clinical oncology. 2011, Vol 29, Num 18, pp 2507-2513, issn 0732-183X, 7 p.Article

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemiaKANTARJIAN, Hagop; RAVANDI, Farhad; JIANQIN SHAN et al.Blood. 2010, Vol 116, Num 22, pp 4422-4429, issn 0006-4971, 8 p.Article

Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous LeukemiaKONOPLEVA, Marina Y; WALTER, Roland B; HONGBO LU et al.Clinical cancer research (Print). 2014, Vol 20, Num 8, pp 2226-2235, issn 1078-0432, 10 p.Article

Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic SyndromeGARCIA-MANERO, Guillermo; TAMBARO, Francesco Paolo; CORTES, Jorge E et al.Journal of clinical oncology. 2012, Vol 30, Num 18, pp 2204-2210, issn 0732-183X, 7 p.Article

Augmented Berlin-Frankfurt-Münster Therapy in Adolescents and Young Adults (AYAs) With Acute Lymphoblastic Leukemia (ALL)RYTTING, Michael E; THOMAS, Deborah A; GARCIA-MANERO, Guillermo et al.Cancer. 2014, Vol 120, Num 23, pp 3660-3668, issn 0008-543X, 9 p.Article

A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemiaKADIA, Tapan M; HUI YANG; NEWSOME, Willie et al.British journal of haematology. 2010, Vol 150, Num 1, pp 72-82, issn 0007-1048, 11 p.Article